Abstract
Glioblastoma multiforme (GBM) is the most common primary tumour of the central nervous system. The outcome after standard therapy, consisting of resection, radiation and chemotherapy, is poor: median survival is 40 to 60 weeks, with the tumour often recurring only a few millimetres away from the original location after gross total resection. The epidermal growth factor receptor (EGFR) is amplified and overexpressed in 40% to 50% of GBM, almost half of which co-expresses the mutated, constitutively activated EGFR variant III (EGFRvIII). As EGFR activation leads to cell proliferation, angiogenesis and reduced apoptosis, its increased activity may contribute to the aggressiveness of GBM. Therefore, to control these carcinogenic functions through EGFR inhibition is a logical therapeutic approach. Various trials of EGFR antagonists are ongoing, investigating tyrosine kinase inhibitors (TKIs), monoclonal antibodies (MAbs), RNA-based agents and vaccination against EGFRvIII. While TKIs, e.g. erlotinib and gefitinib, are currently the most advanced in clinical development, numerous trials indicate that a multiple target approach might be necessary to achieve therapeutically relevant effects.
Keywords: Combined therapy, epidermal growth factor receptor, EGFRvIII, erlotinib, glioblastoma multiforme, multitargeting, tyrosine kinase inhibitors, glioblastoma treatment, RNA-based agents, primary tumor
Current Signal Transduction Therapy
Title: Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Volume: 7 Issue: 1
Author(s): N. Merkur, M.-A. Westhoff, G. Karpel-Massler and M.-E. Halatsch
Affiliation:
Keywords: Combined therapy, epidermal growth factor receptor, EGFRvIII, erlotinib, glioblastoma multiforme, multitargeting, tyrosine kinase inhibitors, glioblastoma treatment, RNA-based agents, primary tumor
Abstract: Glioblastoma multiforme (GBM) is the most common primary tumour of the central nervous system. The outcome after standard therapy, consisting of resection, radiation and chemotherapy, is poor: median survival is 40 to 60 weeks, with the tumour often recurring only a few millimetres away from the original location after gross total resection. The epidermal growth factor receptor (EGFR) is amplified and overexpressed in 40% to 50% of GBM, almost half of which co-expresses the mutated, constitutively activated EGFR variant III (EGFRvIII). As EGFR activation leads to cell proliferation, angiogenesis and reduced apoptosis, its increased activity may contribute to the aggressiveness of GBM. Therefore, to control these carcinogenic functions through EGFR inhibition is a logical therapeutic approach. Various trials of EGFR antagonists are ongoing, investigating tyrosine kinase inhibitors (TKIs), monoclonal antibodies (MAbs), RNA-based agents and vaccination against EGFRvIII. While TKIs, e.g. erlotinib and gefitinib, are currently the most advanced in clinical development, numerous trials indicate that a multiple target approach might be necessary to achieve therapeutically relevant effects.
Export Options
About this article
Cite this article as:
Merkur N., Westhoff M.-A., Karpel-Massler G. and Halatsch M.-E., Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment, Current Signal Transduction Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157436212799278034
DOI https://dx.doi.org/10.2174/157436212799278034 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<sup>90</sup>Y-DOTA-Nimotuzumab: Synthesis of a Promising β− Radiopharmaceutical
Current Radiopharmaceuticals Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies
Current Drug Targets Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design Expression and Function of Bcl-2 Proteins in Melanoma
Current Genomics Can Dietary Antioxidants Reduce the Incidence of Brain Tumors?
Current Drug Metabolism The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy Targeting in the Central Nervous System
Current Gene Therapy Synthesis, Cytotoxicity and Antimicrobial Activity of New Enmein-type Kauranoid Diterpenoid Derivatives
Anti-Cancer Agents in Medicinal Chemistry Unsupervised End-to-End Brain Tumor Magnetic Resonance Image Registration Using RBCNN: Rigid Transformation, B-Spline Transformation and Convolutional Neural Network
Current Medical Imaging The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials The Role of Histone Demethylase GASC1 in Cancer and its Therapeutic Potential
Current Cancer Therapy Reviews Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Membrane Interacting Peptides: A Review
Current Protein & Peptide Science Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Preliminary Analysis of Anti-proliferative, Apoptotic, and Anti-migratory Effects llw-3-6 in Skov-3 Ovarian Cystadenocarcinoma Cell Line
Letters in Drug Design & Discovery The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews